Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy

Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy

Immunotherapy, such as anti-PD1, has improved the survival of patients with metastatic melanoma. However, predicting which patients will respond to immunotherapy remains a significant knowledge gap. In this study we analyzed pre-immunotherapy treated tumors from 52 patients with metastatic melanoma...

Full description

Bibliographic Details
Main Authors: Carol M. Amato, Jennifer D. Hintzsche, Keith Wells, Allison Applegate, Nicholas T. Gorden, Victoria M. Vorwald, Richard P. Tobin, Kelsey Nassar, Yiqun G. Shellman, Jihye Kim, Theresa M. Medina, Matthew Rioth, Karl D. Lewis, Martin D. McCarter, Rene Gonzalez, Aik-Choon Tan, William A. Robinson
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Cancers
Subjects:
immunotherapy
whole exome sequencing
melanoma
RNA sequencing
biomarker
anti-PD1
Online Access:https://www.mdpi.com/2072-6694/12/7/1943

Internet

https://www.mdpi.com/2072-6694/12/7/1943

Similar Items